S-1: A Synergistic Drug Combination that Improves Overall Survival in Patients with Stage II and III Gastric Cancer

S-1 (TS-1) is a chemotherapeutic preparation combining tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1 that significantly improves overall survival in patients with stage II or III gastric cancer. In this study, patients that received S-1 treatment after undergoing a gastrectomy with D2 lymphadenectomy had a 5yr relapse free survival rate of 65.4% compared with 53.1%, and an overall survival rate of 71.7% versus 61.1% for surgery alone. I like this approach because it shows the benefits of using synergistic combinations of drugs that may otherwise only provide limited benefits when used alone.
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer.

Speak Your Mind